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ABSTRACT 
Objective: Depression symptom questionnaires are not for diagnostic classification. Patient 
Health Questionnaire-9 (PHQ-9) scores ≥ 10 are nonetheless often used to estimate depression 
prevalence. We compared PHQ-9 ≥ 10 prevalence to Structured Clinical Interview for DSM 
(SCID) major depression prevalence and assessed whether an alternative PHQ-9 cutoff could 
more accurately estimate prevalence. 
Study design and setting: Individual participant data meta-analysis of datasets comparing PHQ-
9 scores to SCID major depression status.  
Results: 9,242 participants (1,389 SCID major depression cases) from 44 primary studies were 
included. Pooled PHQ-9 ≥ 10 prevalence was 24.6% (95% CI: 20.8%, 28.9%); pooled SCID 
major depression prevalence was 12.1% (95% CI: 9.6%, 15.2%); pooled difference was 11.9% 
(95% CI: 9.3%, 14.6%). Mean study-level PHQ-9 ≥ 10 to SCID-based prevalence ratio was 2.5 
times. PHQ-9 ≥ 14 and the PHQ-9 diagnostic algorithm provided prevalence closest to SCID 
major depression prevalence, but study-level prevalence differed from SCID-based prevalence 
by an average absolute difference of 4.8% for PHQ-9 ≥ 14 (95% prediction interval: -13.6%, 
14.5%) and 5.6 % for the PHQ-9 diagnostic algorithm (95% prediction interval: -16.4%, 15.0%). 
Conclusion: PHQ-9 ≥ 10 substantially overestimates depression prevalence. There is too much 
heterogeneity to correct statistically in individual studies. 
 
Key words: depression prevalence, PHQ-9, SCID, individual participant data meta-analysis 
 
Running title: Depression prevalence based on PHQ-9 vs. SCID  
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HIGHLIGHTS 
• We compared Patient Health Questionnaire-9 (PHQ-9) ≥ 10 prevalence to Structured Clinical 
Interview for DSM (SCID) major depression prevalence in 44 primary studies (9,242 
participants, 1,389 SCID major depression cases) that administered the PHQ-9 and SCID. 
• We also examined whether an alternative PHQ-9 cutoff could more accurately estimate 
prevalence. 
• Pooled PHQ-9 ≥ 10 prevalence (25%) was double pooled SCID major depression prevalence 
(12%); pooled difference from each study was 12%.  
• PHQ-9 ≥ 14 and PHQ-9 diagnostic algorithm prevalence most closely matched SCID major 
depression prevalence, but study-level PHQ-9 ≥ 14 and PHQ-9 diagnostic algorithm 
prevalence differed from SCID major depression prevalence with 95% prediction intervals of 
-14% to 15% and -16% to 15%, respectively. 
• Estimates of depression prevalence should be based on validated diagnostic interviews 
designed for determining case status; users should evaluate published reports of depression 
prevalence to ensure that they are based on methods intended to classify major depression. 
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1. INTRODUCTION 
Disease prevalence estimates have important implications for interpreting medical 
research, understanding disease burden, and making decisions about healthcare resource 
utilization.1 In mental health research, major depression classification requires using validated 
diagnostic interviews.2,3 Administering diagnostic interviews in large enough samples to estimate 
prevalence, however, is resource intensive. Thus, researchers sometimes use self-report 
depression symptom questionnaires, or screening tools, instead, and label the percentage of 
participants scoring above a screening cutoff as depression prevalence.4,5 A 2018 study identified 
19 primary studies listed in PubMed in a 3-month period whose titles indicated that they assessed 
prevalence of depression or depressive disorders and found that 89% were based on screening 
questionnaires only.4 
Some self-report questionnaires include the same symptoms evaluated in validated 
diagnostic interviews. None, however, include all components of diagnostic interviews, such as 
assessment of functional impairment or investigation of non-psychiatric medical conditions that 
can cause similar symptoms.4 Using depression symptom questionnaires and cutoffs intended for 
screening to assess depression prevalence may overestimate prevalence. This is because 
screening attempts to identify previously unrecognized cases; cutoffs are set to cast a wide net 
and identify many more patients who may have depression than meet diagnostic criteria.  
A recent review examined meta-analyses of depression prevalence published in 2008-
2017.5 Of 81 prevalence estimates reported in abstracts of 69 meta-analyses, 10% were based on 
diagnostic interviews, 44% were based on screening or rating tools, and 46% combined results 
from diagnostic interviews and screening or rating tools. Mean reported prevalence was 31% 
among meta-analyses based on screening or rating tools compared to 17% with diagnostic 
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interviews.5 The degree to which screening tools exaggerate prevalence, however, depends on 
the screening tool and cutoff used.4,5 
We do not know of any studies that have evaluated the degree to which specific screening 
tool and cutoff combinations overestimate depression prevalence.4,5 The Patient Health 
Questionnaire-9 (PHQ-9)6-8 is the most commonly used depression screening tool in primary 
care.9 Its nine items align with the Diagnostic and Statistical Manual of Mental Disorders (DSM) 
criteria for major depressive episode.10-12 The standard cutoff, ≥ 10, is well-established for 
screening to detect major depression and maximized combined sensitivity and specificity in a 
recent individual participant data meta-analysis (IPDMA).6-8,13 PHQ-9 ≥ 10 has been used to 
estimate depression prevalence in primary research studies and via synthesis in meta-analyses, 
including in very high-impact journals.14-16 It is also sometimes used to diagnose depression and 
make treatment decisions for individual patients.6,17-19 
Our objective was to use an IPDMA approach to (1) compare PHQ-9 ≥ 10 prevalence to 
major depression prevalence based on a well-validated semi-structured diagnostic interview, the 
Structured Clinical Interview for DSM (SCID);20 and (2) use a prevalence matching approach4,21 
to determine if a PHQ-9 cutoff could be set to match SCID-based prevalence with sufficiently 
low heterogeneity to accurately estimate prevalence in individual studies. 
2. METHODS 
This study used a subset of data accrued for an IPDMA of the accuracy of the PHQ-9 for 
screening to detect major depression.13 Detailed methods were registered in PROSPERO 
(CRD42014010673), and a protocol was published.22 This analysis was not part of the original 
IPDMA protocol.  
2.1 Study Selection 
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In the main IPDMA, datasets from articles in any language were eligible for inclusion if 
(1) they included PHQ-9 scores; (2) they included diagnostic classifications for current Major 
Depressive Episode (MDE) or Major Depressive Disorder (MDD) based on DSM10-12 or 
International Classification of Diseases23 criteria, using a validated semi-structured or fully 
structured interview; (3) the PHQ-9 and diagnostic interview were administered within two 
weeks of each other; (4) participants were ≥18 years and not recruited from youth or school-
based settings; and (5) participants were not recruited from psychiatric settings or because they 
were identified as having depressive symptoms. Datasets where not all participants were eligible 
were included if primary data allowed selection of eligible participants. 
For the present study, we included primary studies that based diagnoses on the SCID.20 
The SCID is a semi-structured diagnostic interview intended to be conducted by an experienced 
diagnostician; it requires clinical judgment and allows rephrasing questions and probes. The 
reason for including only SCID studies is that in analyses using large IPDMA databases,24-26 we 
found that, compared to semi-structured interviews, fully structured interviews, which are 
designed for administration by lay interviewers, identify more participants with low-level 
symptoms as depressed but fewer participants with high-level symptoms. These results were 
consistent with the idea that semi-structured interviews most closely replicate clinical interviews 
done by trained professionals, whereas fully structured interviews are less resource-intensive 
options that can be administered by research staff without diagnostic skills but may misclassify 
major depression in many participants. In our PHQ-9 IPDMA database, 44 of 47 studies that 
used semi-structured interviews used the SCID. Thus, to reduce heterogeneity, we only included 
these 44 studies in main analyses. 
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In sensitivity analyses, we also included the three studies that used other semi-structured 
interviews. We considered also incorporating published results from eligible studies that did not 
contribute data to the IPDMA. However, only 3 of 14 such studies27-29 (970 participants, 77 
major depression cases) reported sufficient information to compare PHQ-9 ≥ 10 and SCID-based 
prevalence, and these studies did not report information necessary to be included in all 
prevalence matching analyses. 
2.2 Data Sources and Searches 
A medical librarian searched Medline, Medline In-Process & Other Non-Indexed Citations 
via Ovid, PsycINFO, and Web of Science from January 1 2000-May 9 2018, using a peer-
reviewed30 search strategy (Supplementary Material: Appendix Methods). We also reviewed 
reference lists of relevant reviews and queried contributing authors about non-published studies.  
Two investigators independently reviewed titles and abstracts for eligibility. If either 
deemed a study potentially eligible, the full-text was reviewed by two investigators, 
independently, with disagreements resolved by consensus, consulting a third investigator when 
necessary. 
2.3 Data Contribution and Synthesis 
Authors of eligible datasets were invited to contribute de-identified primary data, including 
PHQ-9 scores and major depression classification status. We emailed corresponding authors of 
eligible studies at least three times, as necessary. If no response, we emailed co-authors and 
attempted phone contact. 
Prior to integrating individual datasets into our synthesized dataset, we compared published 
participant characteristics and diagnostic accuracy results with results from raw datasets and 
resolved discrepancies with the original investigators. When datasets included statistical weights to 
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reflect sampling procedures, we used provided weights. For studies where sampling procedures 
merited weighting, but the original study did not weight, we constructed weights using inverse 
selection probabilities.  
2.4 Data Analysis 
Comparison of PHQ-9 ≥ 10 Prevalence and SCID Major Depression Prevalence 
For each primary study, we estimated the percentage of participants who scored ≥ 10 on 
the PHQ-9, the percentage of participants classified as having major depression based on the 
SCID, the difference of these percentages, and the ratio. Then, across studies, we pooled 
prevalence for PHQ-9 ≥ 10, prevalence for the SCID, and differences in prevalence. 
Prevalence Matching 
To identify which PHQ-9 scoring approach best matched SCID-based prevalence, we 
estimated pooled differences in prevalence for each possible PHQ-9 cutoff and the PHQ-9 
diagnostic algorithm compared to SCID. The scoring approach with the smallest pooled 
difference was chosen to be the “prevalence match scoring approach.” Then, for each included 
study, we estimated the difference and ratio in prevalence for the prevalence match scoring 
approach versus SCID. We determined the mean and median absolute difference and range of 
differences across all studies. To illustrate the range of difference values that would be expected 
if a new study were to compare prevalence based on the prevalence match scoring approach to 
prevalence based on SCID, we estimated 95% prediction intervals for the differences. For the 
diagnostic algorithm, which requires five or more items with scores of  2 points, with at least 
one being depressed mood or anhedonia,8 three studies31-33 (524 participants) and 88 additional 
participants from other studies (612 participants total, 7%) were excluded, as they did not 
provide PHQ-9 item scores, which are necessary to determine diagnostic algorithm criteria. In 
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sensitivity analyses, we evaluated if results differed if the 612 participants were excluded from 
all analyses rather than just those involving the diagnostic algorithm. 
All meta-analyses incorporated sampling weights and were conducted in R (R version 
3.4.1; R Studio version 1.0.143) using the lme4 package. To estimate pooled prevalence values, 
generalized linear mixed-effects models with a logit link function were fit using the glmer 
function. To estimate pooled difference values, linear mixed-effects models were fit using the 
lmer function. To account for correlation between subjects within the same primary study, 
random intercepts were fit for each primary study. To quantify heterogeneity, we reported the 
estimated between-study variance (τ2) for each analysis.  
In post-hoc analyses, we investigated whether differences in prevalence for the PHQ-9 
prevalence match scoring approach and SCID were associated with study and participant 
characteristics. To do this, we fit additional linear mixed-effects models for pooled prevalence 
difference, including age, sex, country human development index (“very high”, “high”, or “low-
medium”, based on the United Nation’s 2018 Human Development Index) and recruitment 
setting category (primary care, nonmedical care, inpatient specialty care, or outpatient specialty 
care) as fixed-effect covariates. For these analyses, we excluded 56 participants (<1%) missing 
age or sex data. 
3. RESULTS 
3.1 Search Results and Inclusion of Primary Study Datasets 
Of 9,674 unique titles and abstracts identified from the database search for the main 
IPDMA, 9,198 were excluded after title and abstract review and 297 after full-text review, 
leaving 179 eligible articles with data from 123 unique participant samples, of which 95 (77.2%) 
contributed datasets. Authors of included studies contributed data from five unpublished studies, 
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for a total of 100 datasets. Of these, for the present study’s main analyses, we excluded 56 
studies that classified major depression using a diagnostic interview other than the SCID (Figure 
1). Thus, the main analyses of the present study included 9,242 participants (1,389 major 
depression cases) from 44 primary studies.31-72 Among the 28 eligible primary studies that did 
not provide datasets for the main IPDMA, 14 used the SCID (4,408 participants). Thus, the main 
analyses included 75.9% of eligible studies that used the SCID (44 of 58) and 67.7% of eligible 
participants (9,242 of 13,650). Table 1 shows the characteristics of each included study. 
In sensitivity analyses, we included data from three additional studies (1,992 participants; 
139 major depression cases) that provided individual participant data but administered a semi-
structured interview other than the SCID (Table 1)73-75. 
3.2 Comparison of PHQ-9 ≥ 10 Prevalence and SCID Major Depression Prevalence 
The percentage of participants with PHQ-9 ≥ 10 in each of the 44 SCID studies ranged 
from 5.3% to 64.8%; pooled prevalence was 24.6% (95% confidence interval [CI]: 20.8%, 
28.9%; τ2: 0.505). The percentage of participants with SCID major depression ranged from 0.6% 
to 56.4%; pooled prevalence was 12.1% (95% CI: 9.6%, 15.2%; τ2: 0.703). 
Differences in prevalence (PHQ-9 ≥ 10 minus SCID) ranged from -6.0% to 46.9%. The 
pooled difference was 11.9% (95% CI: 9.3%, 14.6%; τ2: 0.007).  
The ratio of PHQ-9 ≥ 10 prevalence to SCID-based prevalence ranged from 0.7 to 10.0 
times (mean: 2.5; median: 1.9). The mean ratio was 3.8 times for the 17 studies with SCID-based 
prevalence < 10% (mean difference: 13.3%), 2.0 times for the 16 studies with SCID-based 
prevalence between 10% and 20% (mean difference: 12.7%), and 1.3 times for the 11 studies 
with SCID-based prevalence of ≥ 20% (mean difference: 8.9%). 
3.3 Prevalence Matching 
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PHQ-9 ≥ 14 (pooled difference in prevalence: 0.5%, 95% CI: -1.7%, 2.6%, τ2: 0.005) and 
the PHQ-9 diagnostic algorithm (pooled difference in prevalence: -0.7%, 95% CI: -3.2%, 1.8%; 
τ2: 0.006) provided prevalence closest to SCID-based prevalence. Pooled differences in 
prevalence for PHQ-9 ≥ 13 and ≥ 15 compared to SCID were 2.6% and -2.0%. 
In the 44 individual SCID studies, differences between the percentage of participants with 
PHQ-9 ≥ 14 and SCID major depression ranged from -18.7% to 29.7% (mean absolute 
difference: 4.8%). Of 44 prevalence estimates based on PHQ-9 ≥ 14, 24 (54.5%) were  0.75 
times or ≥ 1.25 times the SCID-based prevalence. The 95% prediction interval for the difference 
in prevalence was -13.6% to 14.5%. For the PHQ-9 diagnostic algorithm, study-level differences 
in prevalence ranged from -20.1% to 27.1% (mean absolute difference: 5.6%). Of 41 prevalence 
estimates based on the PHQ-9 diagnostic algorithm, 28 (68.3%) were  0.75 times or ≥ 1.25 
times the SCID-based prevalence. The 95% prediction interval for the difference in prevalence 
was -16.4% to 15.0%. No study or participant characteristics were significantly associated with 
differences in prevalence for either of the PHQ-9 prevalence match scoring approaches 
compared to SCID. 
3.4 Sensitivity Analyses 
Results for all analyses were similar when data from the three studies with semi-structured 
interviews other than the SCID were added or when the 612 participants without data to 
determine PHQ-9 diagnostic algorithm classification were excluded. 
4. DISCUSSION 
Primary studies and meta-analyses that describe their results as reflecting prevalence of 
depression or depressive disorders are frequently based on depression screening tools, which are 
not designed for this purpose, rather than validated diagnostic interviews.4,5 The PHQ-9 is often 
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used to generate what are described by researchers as depression prevalence estimates. The 
present study found that using PHQ-9 ≥ 10 to assess depression prevalence, which is commonly 
done, overestimated depression prevalence compared to prevalence based on actual diagnostic 
criteria by 11.9% (mean ratio: 2.5 times). 
These results are consistent with what was predicted in a previous analysis that used 
hypothetical estimates of sensitivity and specificity to demonstrate how depression screening 
tools would be expected to inflate prevalence.4 Results are also consistent with the findings of a 
meta-research review of prevalence estimates from 69 meta-analyses that found higher mean 
depression prevalence based on screening or rating tools than based on diagnostic interviews.5 
Thus, if a screening tool, such as the PHQ-9 ≥ 10, is used to estimate prevalence, prevalence will 
appear to be substantial in virtually all populations, even when true prevalence is very low. This 
could have important ramifications in terms of policies, service planning and healthcare budgets. 
Identifying a PHQ-9 cutoff that could be used to match true prevalence based on a 
diagnostic interview would allow researchers to use inexpensive questionnaires instead of more 
costly interview methods for prevalence estimation. We tested a prevalence matching approach 
and found that PHQ-9 ≥ 14 and the PHQ-9 diagnostic algorithm provided the smallest 
differences in prevalence compared to SCID major depression, but heterogeneity was high and 
not associated with study or participant characteristics. The mean absolute difference between 
prevalence based on PHQ-9 versus SCID in individual studies was 4.8% for PHQ-9 ≥ 14 and 
5.6% for the PHQ-9 diagnostic algorithm, reflecting both overestimation and underestimation. 
For more than half of the studies examined, PHQ-9 ≥ 14 prevalence was less than 75% or more 
than 125% of SCID-based prevalence; for the PHQ-9 diagnostic algorithm the fraction was over 
two-thirds. The 95% prediction interval for the difference between PHQ-9 ≥ 14 and SCID-based 
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prevalence ranged from 14% below to 15% above SCID-based prevalence; for the PHQ-9 
diagnostic algorithm it was from 16% below to 15% above SCID-based prevalence. 
Researchers sometimes report prevalence estimates based on cutoffs from questionnaires, 
including the PHQ-9, as prevalence of “clinically significant” symptoms or “symptoms” of 
depression, rather than “depression”.14,76,77 However, screening tool cutoffs do not reflect a 
meaningful divide between impairment and non-impairment. Patients scoring at or above 
virtually any cutoff would be expected to have greater impairment than patients scoring below 
the cutoff, but no evidence has established any single cutoff for establishing an impairment 
threshold or that would support clinical decision-making for individual patients without a 
validated clinical assessment.4 
Research on screening using the PHQ-9 would be expected to report the proportion of 
patients who score at or above screening cutoffs because this provides information on the 
number of patients who would need resources for further mental health assessment. Reporting 
this percentage as depression prevalence, however, would be akin, for example, to reporting the 
proportion of women with positive mammogram screens as the prevalence of breast cancer and, 
as shown in the present study, would dramatically overestimate prevalence. 
This is the first study to estimate the degree to which using PHQ-9 ≥ 10 to estimate 
depression prevalence, a common practice, leads to overestimation of prevalence. Strengths of 
the study are that we incorporated data from 44 primary studies and that we directly compared 
PHQ-9 ≥ 10 prevalence estimates to those based on the SCID, a rigorous semi-structured 
interview intended to facilitate the standardized application of actual diagnostic criteria by 
trained diagnosticians.10-12 This study had some limitations. First, we were unable to include data 
from 14 of 58 published eligible datasets (24%). Second, included datasets were almost 
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exclusively from patients in healthcare settings where the presence of transdiagnostic somatic 
symptoms and adjustment to illness or injury may have contributed to error variance.75 Third, 
included datasets were from a wide range of study settings, which may account for some of the 
observed heterogeneity. Fourth, overestimation of prevalence when screening tools are used is 
expected to be greater with lower true prevalence. This is because false positives are 
disproportionately high in low-prevalence populations and only minimally offset by false 
negative screens, which occur when true cases are missed by the screening test. However, we 
were unable to assess this because of the small number of heterogeneous datasets included. Fifth, 
not all SCID studies described interviewer qualifications; untrained interviewers may have 
reduced the ability to detect differences across interviews. Sixth, we only examined one 
depression screening tool, the PHQ-9, although we expect that other tools would similarly 
exaggerate depression prevalence.4,5  
In summary, we found that using PHQ-9 ≥ 10 to estimate depression prevalence results in 
estimates that are, on average, 12% greater than what would be obtained using validated semi-
structured diagnostic interviews. Substantial heterogeneity presents a barrier to using statistical 
methods to estimate major depression prevalence based on PHQ-9 ≥ 10 or based on any other 
PHQ-9 cutoff. Researchers should not report results from the PHQ-9 as prevalence of major 
depression. Users of evidence should evaluate reports of prevalence with caution and ensure that 
they are based on methods intended to classify major depression.  
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Table 1. Characteristics of included studies and difference between percentage with PHQ-9 ≥ 10 and prevalence matching-based prevalence 
and prevalence based on diagnostic criteria for major depression 
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Studies from IPDMA that used the SCID and were Included in Main Analyses 




199 70 (8) 117 (59%)  24 (12.1%)  44 (22.1%) 10.1% 1.8  25 (12.6%) 0.5% 1.0  -- -- -- 
Amoozegar, 201734 Canada Migraine 
patients  
203 43 (13) 41 (20%)  49 (24.1%)  72 (35.5%) 11.3% 1.5  40 (19.7%) -4.4% 0.8  36 (17.7%) -6.4% 0.7 
Amtmann, 2015b,35 USA Multiple 
sclerosis 
patients 
164 55 (11) 127 (71%)  48 (17.6%)  90 (33.0%) 15.4% 1.9  55 (20.2%) 2.6% 1.1  42 (15.4%) -2.2% 0.9 
Ayalon, 201036 Israel Elderly primary 
care patients 
151 76 (8) 61 (40%)  6 (4.0%)  14 (9.3%) 5.3% 2.3  7 (4.6%) 0.7% 1.2  6 (4.0%) 0.0% 1.0 
Beraldi, 2014c,37 Germany Cancer 
inpatients 
116 52 (16) 37 (32%)  7 (6.0%)  21 (18.1%) 12.1% 3.0  4 (3.4%) -2.6% 0.6  2 (1.7%) -4.3% 0.3 
Bernstein, 201838 Canada IBD patients 240 49 (15) 151 (63%)  21 (8.8%)  59 (24.6%) 15.8% 2.8  33 (13.8%) 5.0% 1.6  25 (10.4%) 1.7% 1.2 
Bhana, 201539 South Africa Chronic care 
patients 
679 47 (13) 509 (75%)  78 (11.5%)  53 (7.8%) -3.7% 0.7  26 (3.8%) -7.7% 0.3  15 (2.2%) -9.3% 0.2 
Bombardier, 201240 USA Inpatients with 
spinal cord 
injuries 
160 42 (16) 36 (23%)  14 (8.8%)  43 (26.9%) 18.1% 3.1  23 (14.4%) 5.6% 1.6  17 (10.6%) 1.9% 1.2 




84 59 (12) 39 (46%)  19 (22.6%)  30 (35.7%) 13.1% 1.6  16 (19.0%) -3.6% 0.8  12 (14.3%) -8.3% 0.6 




264 38 (10) 208 (79%)  149 (56.4%)  171 (64.8%) 8.3% 1.1  122 (46.2%) -10.2% 0.8  96 (36.4%) -20.1% 0.6 
Eack, 200643 USA Women seeking 
psychiatric 
services for 
their children at 
two mental 
health centers 
48 39 (10) 48 (100%)  12 (25.0%)  24 (50.0%) 25.0% 2.0  17 (35.4%) 10.4% 1.4  17 (35.4%) 10.4% 1.4 
Fann, 2005a,b,e,32 USA Inpatients with 
traumatic brain 
injury 
135 48 (20) 41 (28%)  45 (16.2%)  64 (22.5%) 6.3% 1.4  33 (12.2%) -4.0% 0.8  -- -- -- 
Fiest, 2014e,44 Canada Epilepsy 
outpatients 
169 39 (15) 86 (51%)  23 (13.6%)  37 (21.9%) 8.3% 1.6  17 (10.1%) -3.6% 0.7  17 (10.1%) -3.6% 0.7 
Fischer, 2014f,45 Germany Heart failure 
patients 
194 66 (11) 40 (21%)  11 (5.7%)  37 (19.1%) 13.4% 3.4  19 (9.8%) 4.1% 1.7  20 (10.3%) 4.6% 1.8 
Gjerdingen, 2009 f,46 USA Mothers 
registering their 
newborns for 
419 30 (6) 419 
(100%) 
 19 (4.5%)  49 (11.7%) 7.2% 2.6  26 (6.2%) 1.7% 1.4  31 (7.4%) 2.9% 1.6 
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well-child visits 
at medical or 
pediatric clinics 




494 42 (14) 331 (67%)  67 (13.6%)  166 (33.6%) 20.0% 2.5  97 (19.6%) 6.1% 1.4  86 (17.4%) 3.8% 1.3 
Green, 201748 USA Returning 
veterans 
176 37 (10) 95 (54%)  22 (12.5%)  65 (36.9%) 24.4% 3.0  31 (17.6%) 5.1% 1.4  32 (18.2%) 5.7% 1.5 
Green, 201849 Kenya Pregnant 
women and 
new mothers 
192 27 (6) 192 
(100%) 
 10 (5.2%)  100 (52.1%) 46.9% 10.0  67 (34.9%) 29.7% 6.7  62 (32.3%) 27.1% 6.2 
Haroz, 201750 Myanmar Primary care 
patients 
132 48 (14) 86 (65%)  29 (22.0%)  25 (18.9%) -3.0% 0.9  16 (12.1%) -9.8% 0.6  13 (9.8%) -12.1% 0.4 
Hitchon, 2019h,51 Canada Rheumatoid 
arthritis patients 
148 61 (12) 124 (84%)  16 (10.8%)  44 (29.7%) 18.9% 2.8  22 (14.9%) 4.1% 1.4  26 (17.6%) 6.8% 1.6 
Khamseh, 2011d,i,52 Iran Type 2 diabetes 
patients 
184 56 (9) 96 (52%)  79 (42.9%)  103 (56%) 13.0% 1.3  81 (44.0%) 1.1% 1.0  55 (45.1%) 6.6% 1.2 




113 60 (12) 37 (33%)  3 (2.7%)  24 (21.2%) 18.6% 8.0  9 (8.0%) 5.3% 3.0  7 (6.2%) 3.5% 2.3 
Lambert, 201554 Australia Cancer patients 147 58 (10) 96 (65%)  21 (14.3%)  38 (25.9%) 11.6% 1.8  21 (14.3%) 0.0% 1.0  18 (12.2%) -2.0% 0.9 





280 29 (6) 280 
(100%) 
 29 (10.4%)  57 (20.4%) 10.0% 2.0  21 (7.5%) -2.9% 0.7  23 (8.2%) -2.1% 0.8 
Marrie, 201856 Canada Multiple 
sclerosis 
patients 
244 53 (13) 198 (81%)  25 (10.2%)  73 (29.9%) 19.7% 2.9  43 (17.6%) 7.4% 1.7  36 (14.8%) 4.5% 1.4 
Martin-Subero, 201757 Spain Medical in-
patients 
1003 43 (14) 457 (46%)  83 (8.3%)  289 (28.8%) 20.5% 3.5  154 (15.4%) 7.1% 1.9  143 (14.3%) 6.0% 1.7 
Osório, 200958 Brazil Women in 
primary care 
177 33 (7) 177 
(100%) 
 60 (33.9%)  62 (35%) 1.1% 1.0  45 (25.4%) -8.5% 0.8  43 (24.3%) -9.6% 0.7 
Osório, 201259 Brazil Inpatients from 
various clinical 
wards 
86 49 (12) 35 (41%)  28 (32.6%)  41 (47.7%) 15.1% 1.5  26 (30.2%) -2.3% 0.9  26 (30.2%) -2.3% 0.9 
Patten, 201560 Canada Multiple 
sclerosis 
patients 
143 50 (12) 110 (77%)  20 (14.0%)  36 (25.2%) 11.2% 1.8  24 (16.8%) 2.8% 1.2  12 (8.4%) -5.6% 0.6 
Picardi, 200561 Italy Inpatients with 
skin diseases 
138 37 (13) 77 (56%)  12 (8.7%)  38 (27.5%) 18.8% 3.2  21 (15.2%) 6.5% 1.8  18 (13.0%) 4.3% 1.5 




114 60 (16) 64 (56%)  11 (9.6%)  16 (14%) 4.4% 1.5  11 (9.6%) 0.0% 1.0  9 (7.9%) -1.8% 0.8 
Quinn, Unpublishedh,j UK Stroke patients 146 68 (13) 65 (47%)  17 (11.6%)  43 (29.5%) 17.8% 2.5  17 (11.6%) 0.0% 1.0  17 (12.6%) 1.5% 1.1 






377 77 (9) 258 (68%)  95 (25.2%)  117 (31%) 5.8% 1.2  65 (17.2%) -8.0% 0.7  60 (15.9%) -9.3% 0.6 
Rooney, 201364 UK Adults with 
cerebral glioma 
126 54 (12) 54 (43%)  14 (11.1%)  27 (21.4%) 10.3% 1.9  15 (11.9%) 0.8% 1.1  13 (10.3%) -0.8% 0.9 
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Shinn, 2017k,65 USA Cancer patients 139 59 (11) 139 
(100%) 
 12 (8.6%)  24 (17.3%) 8.6% 2.0  11 (7.9%) -0.7% 0.9  8 (6.5%) 2.4% 1.6 
Sidebottom, 2012l,66 USA Pregnant 
women 
246 25 (5) 246 
(100%) 
 12 (4.9%)  59 (24%) 19.1% 4.9  32 (13.0%) 8.1% 2.7  32 (13.0%) 8.1% 2.7 
Simning, 201267 USA Older adults 
living in public 
housing 
190 68 (7) 110 (58%)  10 (5.3%)  25 (13.2%) 7.9% 2.5  11 (5.8%) 0.5% 1.1  9 (4.7%) -0.5% 0.9 
Spangenberg, 201568 Germany Primary care 
patients 
160 72 (6) 97 (61%)  1 (0.6%)  9 (5.6%) 5.0% 9.0  4 (2.5%) 1.9% 4.0  4 (2.5%) 1.9% 4.0 
Turner, 201269 Australia Stroke patients 72 67 (13) 34 (47%)  13 (18.1%)  22 (30.6%) 12.5% 1.7  12 (16.7%) -1.4% 0.9  9 (12.5%) -5.6% 0.7 
Turner, Unpublishedh Australia Cardiac 
rehabilitation 
patients 
51 60 (12) 7 (14%)  4 (7.8%)  6 (11.8%) 3.9% 1.5  2 (3.9%) -3.9% 0.5  2 (3.9%) -3.9% 0.5 
Vöhringer, 2013a,33 Chile Primary care 
patients 
190 50 (17) 143 (75%)  59 (31.1%)  85 (44.7%) 13.7% 1.4  54 (28.4%) -2.6% 0.9  -- -- -- 





54 59 (11) 38 (69%)  6 (4.3%)  13 (5.3%) 0.9% 1.2  7 (2.8%) -1.5% 0.7  6 (2.4%) -1.9% 0.6 
Williams, 201271 USA Parkinson’s 
Disease patients  
235 66 (10) 76 (32%)  61 (26.0%)  47 (20.0%) -6.0% 0.8  17 (7.2%) -18.7% 0.3  17 (7.2%) -18.7% 0.3 
Wittkampf, 2009b,72 Netherlands Primary care 
patients at risk 
for depression 
260 51 (12) 175 (64%)  45 (11.6%)  90 (22.2%) 10.6% 1.9  49 (11.6%) 0.0% 1.0  44 (10.4%) -1.2% 0.9 
Studies from IPDMA that used other Semi-structured Interviews and were Included in Sensitivity Analyses 
Liu, 2011m,73 Taiwan Primary care 
patients 
1532 53 (19) 933 (61%)  50 (3.3%)  133 (8.7%) 5.4% 2.7  46 (3.0%) -0.3% 0.9  50 (3.3%) 0.0% 1.0 
McGuire, 2013n,74 USA Acute coronary 
syndrome 
inpatients 
100 63 (12) 31 (31%)  9 (9.0%)  25 (25.0%) 16.0% 2.8  13 (13.0%) 4.0% 1.4  12 (12.0%) 3.0% 1.3 
Twist, 2013b,c,m,o,75 UK Type 2 diabetes 
outpatients 
360 56 (11) 172 (45%)  80 (7.4%)  178 (14.8%) 7.4% 2.0  112 (9.3%) 1.9% 1.3  97 (8.2%) 0.7% 1.1 
aStudy did not provide item-level data necessary to determine classification based on the PHQ-9 diagnostic algorithm 
bSampling weights were applied. Counts are based on actual numbers, whereas percentages are weighted 
c1 participant missing data for age 
d10 participants missing data for age 
e1 participant missing data for both age and sex 
f2 participants missing data for age 
g21 participants missing data for age 
hUnpublished at the time of electronic database search 
i62 participants missing data to determine classification based on the PHQ-9 diagnostic algorithm 
j2 participants missing data for age, 7 participants missing data for sex, 10 participants missing data to determine classification based on the PHQ-9 diagnostic algorithm, and 1 participant missing data for age, sex and 
diagnostic algorithm 
k2 participants missing data for age, 14 participants missing data to determine classification based on the PHQ-9 diagnostic algorithm, and 1 participant missing data for age and diagnostic algorithm  
l4 participants missing data for age 
mDiagnostic interview: Schedules for Clinical Assessment in Neuropsychiatry 
nDiagnostic interview: Depression Interview and Structured Hamilton 
o8 participants missing data to determine classification based on the PHQ-9 diagnostic algorithm 
Abbreviations: DA+: positive classification based on PHQ-9 diagnostic algorithm 
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FIGURE LEGENDS 
Figure 1. Flow diagram of study selection process 
 
